PURPOSE: To evaluate the clinical experience with @entity1499 as a first-line corticosteroid-sparing drug in @entity1 with @entity32 . METHODS: We retrospectively studied 39 consecutive @entity1 with @entity1596 (n = 36) or @entity3170 (n = 3) who were treated with @entity1499 following inadequate control with @entity288 lasting five years. Criteria for initiating treatment with @entity1499 and defining outcome were strictly defined. RESULTS: The cohort included 21 females and 18 males, all Caucasians, with a mean age of 26.6 years (range: 3-73 years). @entity1 were followed up for 21.5 +/- 12.6 months. Treatment was discontinued due to side effects in 10 @entity1 (26%). Of the remaining 29 @entity1 , full or partial control of @entity32 was achieved in 23 (79%). Response to treatment was observed after a mean of 2.4 +/- 0.8 months. Ten @entity1 were fully controlled and discontinued @entity1499 therapy after a mean of 20.9 +/- 9.2 months, with no recurrence of @entity32 . Use of topical and systemic @entity288 was markedly reduced in responsive @entity1 . CONCLUSIONS: @entity1499 is recommended as a first-line adjunct to or replacement of systemic @entity288 in the treatment of @entity32 .

@entity1499 as a first-line corticosteroid-sparing therapy in a cohort of @entity1596 and XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['resistant ocular inflammation', 'inflammation', 'ocular inflammation'] @entity1596 :: ('MESH:D014605', 'Disease') :: ['uveitis'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate', 'methotrexate'] @entity3170 :: ('MESH:D015423', 'Disease') :: ['scleritis'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity3170 :: (MESH:D015423,Disease) :: ['scleritis']
